PeptideInfo
العربيةGet the app
☰
Hormonal & EndocrineApproved (US)

HGH (Somatropin)

Somatropin · Human Growth Hormone · rhGH

Somatropin activates the GH receptor and then JAK2/STAT signaling. IGF-1 production rises both in the liver and in peripheral tissues. Downstream effects promote protein production, fat breakdown and remodeling of connective tissue.

Not medical advice. Educational reference only.

Typical dose
1–2 IU daily or five times weekly; 2–4 IU daily; 0.15–0.3 mg daily for GHD; 4–6 IU daily short-term: all subcutaneous
Route
Subcutaneous injection
Storage
Keep at 2–8°C after mixing and use within 28 days.

What is HGH (Somatropin)?

Somatropin, or recombinant human growth hormone (rhGH), reproduces the endogenous hormone. Clinical treatment addresses growth hormone deficiency and certain catabolic conditions. Extensive evidence covers children and adults with GHD, while registries continue to track longer-term outcomes. Off-label applications for aging and body composition remain medically controversial; obtain physician supervision for any such use.

Mechanism of action

Somatropin activates the GH receptor and then JAK2/STAT signaling. IGF-1 production rises both in the liver and in peripheral tissues. Downstream effects promote protein production, fat breakdown and remodeling of connective tissue.

Targets: Growth hormone receptor (GHR) · IGF-1 axis

Research indications

  • Hormonal Regulation

    Most effective

    Direct endocrine activity produces effects on hormone regulation that are well characterized.

  • Reproductive Health

    Effective

    Fertility investigations and reproductive medicine are areas of research and clinical application.

  • Metabolic Support

    Moderate

    Hormonal signaling may produce secondary effects on metabolic function.

Research protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalAmountFrequencyRoute
Wellness / Anti-Aging1–2 IUDaily or 5x weeklySubcutaneous injection
Body Composition2–4 IUDaily (often split AM/PM)Subcutaneous injection
Clinical GHD Replacement0.15–0.3 mgDailySubcutaneous injection
Performance (advanced)4–6 IUDaily, short-termSubcutaneous injection

Interactions

  • Medications

    Caution

    Consult your prescriber before combining this compound with any medication.

  • BPC-157

    Compatible

  • NAD+

    Compatible

  • Vitamin D

    Compatible

How to reconstitute and inject

Diluent: Use bacteriostatic water only; avoid saline because precipitation can occur.

  1. Let the refrigerated vial warm to room temperature for 15–20 minutes before preparing it.
  2. Disinfect the stopper using an alcohol swab, then wait until the surface has dried fully in the air.
  3. Use a sterile syringe to measure your calculated amount of bacteriostatic water. Use this diluent only; avoid saline because precipitation may occur.
  4. Introduce the water gradually against the inner glass wall. Keep the stream away from the peptide powder itself.
  5. Rotate the vial gently to mix its contents. Do not shake forcefully, because vigorous agitation can degrade the peptide.
  6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
  7. Measure your calculated dose with an insulin syringe in preparation for administration beneath the skin.
  8. Use the abdomen, thigh or upper arm for subcutaneous administration. Change the injection location each time to help prevent lipodystrophy.
  9. Return the mixed vial to refrigeration at 2–8°C. Use the prepared solution within 28 days of mixing.

What to expect

Week 1–2
Early effects may accompany an adjustment period. Watch for any unwanted reaction as you adapt.
Week 2–4
The principal effects may begin emerging. Follow your clinician’s recommendations for any change in dose.
Week 4–8
Main effects are expected to be apparent at this stage. Review your progress together with your clinician.
Week 8+
Review the outcome with your clinician and decide whether to continue, take a cycle break or adjust the dose. These timings do not establish effectiveness for every compound.

Side effects and safety

  • Bruising, redness or mild soreness where the injection is given
  • Possible allergic response; stop use if you develop hives or a rash
  • Variable individual response; begin with the lowest dose and watch closely for reactions
  • Discuss use with your clinician beforehand and report symptoms that are unusual for you

HGH (Somatropin): approved in the US.

Regulatory status

  • US

    Approved

    FDA — approval applies to specific indications for prescription somatropin, including growth hormone deficiency and selected catabolic conditions. This approval does not establish anti-aging or performance regimens.

    Rx required
    Yes
    Telehealth
    Available

Frequently asked questions

What is HGH (Somatropin)?

Somatropin is recombinant GH used as prescription replacement in diagnosed deficiency and in selected catabolic conditions.

Which dose ranges are commonly discussed?

Wellness discussions include 1–2 IU daily, while body-composition discussions include 2–4 IU daily. Replacement for diagnosed GHD is directed by a physician and often expressed in mg per day. A clinician must individualize the protocol; these research schedules are not a prescription.

What monitoring accompanies somatropin?

Track IGF-1, fasting glucose or A1C, fluid accumulation and blood pressure. Report joint discomfort and symptoms resembling carpal tunnel syndrome. This monitoring helps identify excessive treatment and supports individual dose adjustment.

What about combinations with LR3 or secretagogues?

Advanced protocols sometimes combine these agents, but multiple GH-axis compounds increase both complexity and risk. Metabolic effects may intensify. Obtain clinician oversight and objective laboratory monitoring for any combination.

References

  1. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline (2011)

  2. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis. (2023)

    PMID 37236413DOI 10.1016/j.phrs.2023.106805

  3. Acromegaly. (2019)

    PMID 30899019DOI 10.1038/s41572-019-0071-6